ArticleCancer immunology research2020
B cell-Derived IL35 Drives STAT3-Dependent CD8
Open access · greenAbstract read
In one paragraph
Article in Cancer immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 108 citations in OpenAlex.
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Reprogramming pulmonary B cells by ANXA1 silencing halts lung metastatic niche formation in breast cancer.Journal of nanobiotechnology · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy.iScience · 2026Review
- Humoral immunity in pancreatic cancer: B-cell heterogeneity, regulatory networks, and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- Regulatory B Cells at the Crossroads of Epigenetic Control and Immune Homeostasis.Clinical reviews in allergy & immunology · 2026Review
- Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment.Journal for immunotherapy of cancer · 2026Review
- Tumor-infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors.International journal of cancer · 2026Review
- The Role of B Cells in Tumorigenesis and Immunotherapy.Immune network · 2026Review
- Interleukin 35 promotes progression of hepatocellular carcinoma by recruiting neutrophils.Translational oncology · 2026Article
- Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic.Frontiers in immunology · 2026Review
- Dynamic regulation of hypoxia-associated regulatory CD39Frontiers in immunology · 2026Article
- The Significance of STAT3 in Colonic Diseases: A Comprehensive Study of Pathological Roles and Therapeutic Implications.Cell biochemistry and biophysics · 2025Review
- Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy.Cell death & disease · 2025Review
- Influence and Role of Regulatory B Cells in Organ Transplantation: The State of the Art, Prospects, and Emerging Insights.Antibodies (Basel, Switzerland) · 2025Review
- Review
- Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions.Molecular cancer · 2025Review
- Regulatory B cells drive immune evasion in the tumor microenvironment and are involved peritoneal metastasis in gastric cancer.Scientific reports · 2025Article
- Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Bhalchandra MirlekarLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Daniel MichaudDepartment of Cell Biology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Samuel J LeeLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.ORCID 0000-0003-2536-2684
Nancy P KrenLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Cameron HarrisLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Kevin GreeneDepartment of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Emily C GoldmanDepartment of Radiation Oncology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Gaorav P GuptaLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Ryan C FieldsDepartment of Surgery, Barnes-Jewish Hospital and the Alvin J. Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
William G HawkinsDepartment of Surgery, Barnes-Jewish Hospital and the Alvin J. Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
David G DeNardoDepartment of Medicine, Barnes-Jewish Hospital and the Alvin J. Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Naim U RashidLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Jen Jen YehLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Autumn J McReeLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Benjamin G VincentLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Dario A A VignaliDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-2771-5992
Yuliya Pylayeva-GuptaLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina. yuliyap1@email.unc.edu.
University of North Carolina at Chapel Hill · USJewish Hospital · USUniversity of Pittsburgh · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI FIELDS, RYAN C · 2016 to 2020
$10.9MCANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0MTumor Subtypes and Therapy Response in Pancreatic CancerR01CA199064 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TSAI, SUSAN, YEH, JEN JEN · 2016 to 2021
$4.4MThe Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic CancerR01CA177670 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G · 2014 to 2023
$3.3MFunction of IL35+ B cells in pancreatic cancerR37CA230786 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PYLAYEVA-GUPTA, YULIYA · 2019 to 2025
$3.0MExploiting Integrin Signaling to Overcome Resistance to ImmunotherapyR01CA244938 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G, GUPTA, VINEET · 2020 to 2024
$2.2MDuke-UNC Chapel Hill Immunotherapy Training GrantT32CA211056 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAO, NELSON J., SERODY, JONATHAN S. · 2017 to 2021
$2.2MInterleukin-35 and the tumor microenvironmentR01CA203689 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VIGNALI, DARIO AA · 2016 to 2020
$1.9MCOMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPYR01CA203890 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G · 2016 to 2020
$1.7MMechanisms of B cell specific IL-35 expression in cancer.F31CA239494 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MICHAUD, DANIEL E · 2020 to 2021
$62kNCI NIH HHS F31 CA239494NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA196510NCI NIH HHS R01 CA177670NCI NIH HHS R01 CA199064NCI NIH HHS R01 CA203689NCI NIH HHS R01 CA203890NCI NIH HHS R01 CA244938NCI NIH HHS R37 CA230786NCI NIH HHS T32 CA071341NCI NIH HHS T32 CA211056
Abstract
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy characterized by a paucity of tumor-proximal CD8
Indexed as
AnimalsApoptosisB-LymphocytesCarcinoma, Pancreatic DuctalCase-Control StudiesCD8-Positive T-LymphocytesCell ProliferationHumansImmunotherapy, AdoptiveInterleukinsLymphocyte ActivationLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLPancreatic NeoplasmsReceptors, CCR5CCR5 protein, humanCCR5 protein, mouseCXCR3 protein, humanCxcr3 protein, mouseinterleukin-35, humaninterleukin-35, mouseInterleukinsReceptors, CCR5Receptors, CXCR3STAT3 protein, humanStat3 protein, mouseSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.